CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade G1 Therapeutics - GTHX CFD

    3.14
    31.93%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    G1 Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 2.38
    Open* 2.41
    1-Year Change* -61.87%
    Day's Range* 2.41 - 3.18
    52 wk Range 1.08-8.40
    Average Volume (10 days) 478.73K
    Average Volume (3 months) 11.23M
    Market Cap 84.35M
    P/E Ratio -100.00K
    Shares Outstanding 51.81M
    Revenue 77.89M
    EPS -1.47
    Dividend (Yield %) N/A
    Beta 1.75
    Next Earnings Date Feb 28, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 6, 2023 2.38 0.54 29.35% 1.84 2.46 1.84
    Dec 5, 2023 1.81 -0.16 -8.12% 1.97 1.97 1.79
    Dec 4, 2023 1.97 -0.01 -0.51% 1.98 2.09 1.92
    Dec 1, 2023 1.97 0.12 6.49% 1.85 1.97 1.78
    Nov 30, 2023 1.86 0.16 9.41% 1.70 1.90 1.70
    Nov 29, 2023 1.68 0.01 0.60% 1.67 1.74 1.66
    Nov 28, 2023 1.67 0.06 3.73% 1.61 1.68 1.57
    Nov 27, 2023 1.62 -0.05 -2.99% 1.67 1.67 1.61
    Nov 24, 2023 1.67 0.04 2.45% 1.63 1.69 1.61
    Nov 22, 2023 1.63 0.00 0.00% 1.63 1.67 1.59
    Nov 21, 2023 1.61 0.01 0.63% 1.60 1.69 1.55
    Nov 20, 2023 1.60 0.04 2.56% 1.56 1.87 1.54
    Nov 17, 2023 1.53 -0.01 -0.65% 1.54 1.54 1.49
    Nov 16, 2023 1.54 -0.04 -2.53% 1.58 1.60 1.51
    Nov 15, 2023 1.61 0.03 1.90% 1.58 1.73 1.58
    Nov 14, 2023 1.59 0.16 11.19% 1.43 1.59 1.43
    Nov 13, 2023 1.42 0.05 3.65% 1.37 1.44 1.34
    Nov 10, 2023 1.38 0.02 1.47% 1.36 1.41 1.29
    Nov 9, 2023 1.31 -0.15 -10.27% 1.46 1.53 1.29
    Nov 8, 2023 1.43 -0.10 -6.54% 1.53 1.54 1.40

    G1 Therapeutics Events

    Time (UTC) Country Event
    Wednesday, February 28, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 G1 Therapeutics Inc Earnings Release
    Q4 2023 G1 Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 51.301 31.476 45.285 0 0
    Revenue 51.301 31.476 45.285 0 0
    Total Operating Expense 187.479 173.733 141.761 129.041 89.286
    Selling/General/Admin. Expenses, Total 101.033 96.491 69.445 40.648 18.603
    Research & Development 82.698 75.426 72.316 88.393 70.683
    Operating Income -136.178 -142.257 -96.476 -129.041 -89.286
    Other, Net 0.003 -0.546 -0.542 6.594 3.998
    Net Income Before Taxes -145.859 -147.427 -97.844 -122.447 -85.288
    Net Income After Taxes -147.559 -148.352 -99.254 -122.447 -85.288
    Net Income Before Extra. Items -147.559 -148.352 -99.254 -122.447 -85.288
    Net Income -147.559 -148.352 -99.254 -122.447 -85.288
    Total Adjustments to Net Income 0 0 0
    Income Available to Common Excl. Extra. Items -147.559 -148.352 -99.254 -122.447 -85.288
    Income Available to Common Incl. Extra. Items -147.559 -148.352 -99.254 -122.447 -85.288
    Dilution Adjustment
    Diluted Net Income -147.559 -148.352 -99.254 -122.447 -85.288
    Diluted Weighted Average Shares 43.6261 41.9434 37.878 37.4993 33.3167
    Diluted EPS Excluding Extraordinary Items -3.38235 -3.53696 -2.62036 -3.26532 -2.55992
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -3.38235 -3.54005 -2.62036 -3.26532 -2.55992
    Interest Income (Expense), Net Non-Operating -9.684 -4.624 -0.826
    Cost of Revenue, Total 3.748 2.016
    Gross Profit 47.553 29.46
    Unusual Expense (Income) -0.2
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 42.392 12.946 10.25 23.576 10.573
    Revenue 42.392 12.946 10.25 23.576 10.573
    Cost of Revenue, Total 1.404 1.459 0.992 1.111 0.976
    Gross Profit 40.988 11.487 9.258 22.465 9.597
    Total Operating Expense 30.876 38.692 41.137 45.124 47.535
    Selling/General/Admin. Expenses, Total 17.432 21.753 23.558 24.432 25.716
    Research & Development 12.04 15.48 16.587 19.581 20.843
    Operating Income 11.516 -25.746 -30.887 -21.548 -36.962
    Interest Income (Expense), Net Non-Operating -2.067 -2.373 -2.518 -2.553 -2.357
    Other, Net 0.569 0.524 0.237 0.048 -0.127
    Net Income Before Taxes 10.018 -27.595 -33.168 -24.053 -39.446
    Net Income After Taxes 8.71 -27.595 -33.649 -25.272 -39.446
    Net Income Before Extra. Items 8.71 -27.595 -33.649 -25.272 -39.446
    Net Income 8.71 -27.595 -33.649 -25.272 -39.446
    Income Available to Common Excl. Extra. Items 8.71 -27.595 -33.649 -25.272 -39.446
    Income Available to Common Incl. Extra. Items 8.71 -27.595 -33.649 -25.272 -39.446
    Diluted Net Income 8.71 -27.595 -33.649 -25.272 -39.446
    Diluted Weighted Average Shares 61.0405 51.6479 46.309 42.7993 42.7077
    Diluted EPS Excluding Extraordinary Items 0.14269 -0.53429 -0.72662 -0.59048 -0.92363
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS 0.14269 -0.53429 -0.72662 -0.59048 -0.92363
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 179.5 243.565 216.392 271.003 370.133
    Cash and Short Term Investments 145.07 221.186 207.306 269.208 369.29
    Cash & Equivalents 94.594 221.186 207.306 269.208 369.29
    Prepaid Expenses 7.094 13.157 8.786 1.732 0.843
    Total Assets 187.965 254.094 228.552 284.831 371.27
    Property/Plant/Equipment, Total - Net 7.951 9.048 10.508 13.391 1.137
    Property/Plant/Equipment, Total - Gross 9.777 10.344 11.335 14.068 1.459
    Accumulated Depreciation, Total -1.826 -1.296 -0.827 -0.677 -0.322
    Total Current Liabilities 35.588 27.613 23.443 19.769 12.362
    Accounts Payable 7.431 2.897 3.572 3.684 3.377
    Accrued Expenses 26.692 24.295 17.474 16.085 8.985
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 1.465 0.421 2.397
    Total Liabilities 119.218 110.553 51.201 29.304 12.45
    Total Long Term Debt 77.015 75.19 19.893 0 0
    Total Equity 68.747 143.541 177.351 255.527 358.82
    Redeemable Preferred Stock
    Common Stock 0.005 0.004 0.004 0.004 0.004
    Retained Earnings (Accumulated Deficit) -732.018 -584.459 -436.107 -336.853 -214.406
    Treasury Stock - Common -0.008 -0.008 -0.008 -0.008 -0.008
    Total Liabilities & Shareholders’ Equity 187.965 254.094 228.552 284.831 371.27
    Total Common Shares Outstanding 51.4994 42.5621 38.1141 37.6116 37.2421
    Other Liabilities, Total 6.615 7.75 7.865 9.535 0.088
    Additional Paid-In Capital 800.768 728.004 613.462 592.384 573.23
    Other Current Assets, Total 0.063 0.063 0.063 0.063
    Other Long Term Assets, Total 0.514 1.481 1.652 0.437
    Total Receivables, Net 11.094 5.688 0.237
    Accounts Receivable - Trade, Net 11.094 5.688 0.237
    Long Term Debt 77.015 75.19 19.893
    Total Inventory 16.179 3.471
    Short Term Investments 50.476
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 126.103 140.436 153.965 179.5 157.465
    Cash and Short Term Investments 94.352 104.231 116.317 145.07 122.982
    Cash & Equivalents 52.623 55.914 68.237 94.594 93.238
    Total Receivables, Net 9.265 13.171 16.025 11.094 10.521
    Accounts Receivable - Trade, Net 9.265 13.171 16.025 11.094 10.521
    Total Inventory 13.491 15.6 15.543 16.179 13.95
    Prepaid Expenses 8.932 7.371 6.017 7.094 9.949
    Other Current Assets, Total 0.063 0.063 0.063 0.063 0.063
    Total Assets 133.097 147.891 161.957 187.965 166.573
    Property/Plant/Equipment, Total - Net 6.78 7.173 7.564 7.951 8.365
    Property/Plant/Equipment, Total - Gross 8.995 9.261 9.522 9.777 10.054
    Accumulated Depreciation, Total -2.215 -2.088 -1.958 -1.826 -1.689
    Other Long Term Assets, Total 0.214 0.282 0.428 0.514 0.743
    Total Current Liabilities 33.653 33.912 33.69 35.588 37.134
    Accounts Payable 7.335 5.762 5.38 7.431 8.442
    Accrued Expenses 24.181 24.681 22.767 26.692 27.251
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 2.137 3.469 5.543 1.465 1.441
    Total Liabilities 90.075 90.343 116.969 119.218 120.608
    Total Long Term Debt 51.246 50.936 77.47 77.015 76.558
    Long Term Debt 51.246 50.936 77.47 77.015 76.558
    Other Liabilities, Total 5.176 5.495 5.809 6.615 6.916
    Total Equity 43.022 57.548 44.988 68.747 45.965
    Common Stock 0.005 0.005 0.005 0.005 0.004
    Additional Paid-In Capital 812.132 808.454 804.604 800.768 744.338
    Retained Earnings (Accumulated Deficit) -769.107 -750.903 -759.613 -732.018 -698.369
    Treasury Stock - Common -0.008 -0.008 -0.008 -0.008 -0.008
    Total Liabilities & Shareholders’ Equity 133.097 147.891 161.957 187.965 166.573
    Total Common Shares Outstanding 51.8099 51.7085 51.6593 51.4994 42.8971
    Short Term Investments 41.729 48.317 48.08 50.476 29.744
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -147.559 -148.352 -99.254 -122.447 -85.288
    Cash From Operating Activities -128.62 -132.108 -83.742 -99.571 -74.307
    Cash From Operating Activities 0.53 0.469 0.582 0.356 0.175
    Non-Cash Items 23.716 24.613 19.006 16.449 10.233
    Changes in Working Capital -5.307 -8.838 -4.076 6.071 0.573
    Cash From Investing Activities -50.529 0 0.152 -2.716 -0.709
    Capital Expenditures -0.506 0 -2.716 -0.709
    Cash From Financing Activities 52.495 145.863 21.688 2.705 340.494
    Financing Cash Flow Items -0.043 -1.411 -0.62 0 -0.892
    Issuance (Retirement) of Stock, Net 52.538 92.274 2.308 2.705 341.386
    Net Change in Cash -126.654 13.755 -61.902 -99.582 265.478
    Cash Interest Paid 7.924 2.908 0.997
    Other Investing Cash Flow Items, Total -50.023 0 0.152
    Issuance (Retirement) of Debt, Net 0 55 20
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -27.595 -147.559 -113.91 -88.638 -49.192
    Cash From Operating Activities -29.053 -128.62 -97.988 -76.741 -38.184
    Cash From Operating Activities 0.132 0.53 0.393 0.254 0.115
    Non-Cash Items 4.75 23.716 18.876 13.433 7.071
    Cash Interest Paid 2.512 7.924 5.61 3.537 1.716
    Changes in Working Capital -6.34 -5.307 -3.347 -1.79 3.822
    Cash From Investing Activities 2.91 -50.529 -30.167 -0.506 0
    Capital Expenditures -0.506 -0.506 -0.506
    Cash From Financing Activities -0.214 52.495 0.145 0.018 0.018
    Financing Cash Flow Items -0.215 -0.043 0 0 0
    Issuance (Retirement) of Stock, Net 0.001 52.538 0.145 0.018 0.018
    Issuance (Retirement) of Debt, Net 0 0 0 0
    Net Change in Cash -26.357 -126.654 -128.01 -77.229 -38.166
    Other Investing Cash Flow Items, Total 2.91 -50.023 -29.661 0
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Eshelman Ventures LLC Corporation 8.7275 4516074 1076923 2023-03-31
    MedImmune Ventures, Inc. Venture Capital 5.7022 2950630 0 2023-03-31 LOW
    Fisher Investments Investment Advisor/Hedge Fund 4.9144 2543006 -181704 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.7686 1950068 -29660 2023-06-30 LOW
    JP Morgan Asset Management Investment Advisor 3.5172 1820015 -29832 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 2.1624 1118965 -57089 2023-06-30 LOW
    Raymond James & Associates, Inc. Research Firm 1.7891 925776 133662 2023-09-30 LOW
    D. E. Shaw & Co., L.P. Hedge Fund 1.1914 616503 186864 2023-06-30 MED
    Millennium Management LLC Hedge Fund 1.1751 608065 -267069 2023-06-30 HIGH
    Renaissance Technologies LLC Hedge Fund 1.105 571791 128816 2023-06-30 HIGH
    Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 0.9523 492776 209541 2023-06-30 MED
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.8342 431652 -6742 2023-06-30 LOW
    Tekla Capital Management LLC Investment Advisor 0.8191 423869 0 2023-06-30 LOW
    BofA Global Research (US) Research Firm 0.6191 320346 -283072 2023-06-30 LOW
    GSA Capital Partners LLP Hedge Fund 0.5141 266017 266017 2023-06-30 HIGH
    Bailey (John E JR) Individual Investor 0.4778 247252 -2719 2023-07-05 MED
    Charles Schwab Investment Management, Inc. Investment Advisor 0.4631 239609 35245 2023-06-30 LOW
    Needham Investment Management L.L.C. Investment Advisor/Hedge Fund 0.4522 234000 0 2023-06-30 LOW
    Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.4362 225700 225700 2022-12-31 LOW
    JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 0.4294 222182 -133 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    G1 Therapeutics Company profile

    About G1 Therapeutics Inc

    G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead compound COSELA (trilaciclib), is a therapy designed to help protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lunger cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. The Company's Rintodestrant, is a clinical-stage oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-breast cancer.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, G1 Therapeutics Inc revenues decreased 30% to $31.5M. Net loss increased 49% to $148.4M. Revenues reflect License revenue decrease of 55% to $20.4M. Higher net loss reflects General and Administrative - Balancing increase of 40% to $77.6M (expense), Stock-based Compensation in SGA increase of 45% to $17.3M (expense), Research & Development - Balancing value increase of 8% to $70.6M (expense).

    Industry: Bio Therapeutic Drugs

    700 Park Offices Drive
    Suite 200
    RESEARCH TRIANGLE PARK
    NORTH CAROLINA 27709
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    US100

    15,997.80 Price
    +1.310% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    XRP/USD

    0.65 Price
    +0.990% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Gold

    2,031.44 Price
    +0.260% 1D Chg, %
    Long position overnight fee -0.0197%
    Short position overnight fee 0.0115%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    Oil - Crude

    70.33 Price
    +1.240% 1D Chg, %
    Long position overnight fee -0.0205%
    Short position overnight fee -0.0014%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading